Novavax Launches Coronavirus Vaccine Phase 2b Study in South Africa

Novavax, Inc. announced on August 17, 2020, a Phase 2b clinical trial is launching in South Africa to evaluate the efficacy of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. Dr. Shabir Madhi, Professor of Vaccinology at Wits University, will lead the clinical trial. Novavax said it expects that, if approved in South Africa, its COVID-19 vaccine would ultimately be supplied to South Africa through Novavax’s recently announced collaboration with the Serum Institute of India.